Abstract
In November 2011, tafamidis (Vyndaqel; Pfizer), a small molecule that inhibits the dissociation of transthyretin tetramers, was granted marketing authorization by the European Commission for the treatment of transthyretin amyloidosis in adult patients with stage 1 symptomatic polyneuropathy to delay peripheral neurological impairment.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature
Journal of Neurology Open Access 04 June 2020
-
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
Orphanet Journal of Rare Diseases Open Access 17 January 2018
-
Glial cells in familial amyloidotic polyneuropathy
Acta Neuropathologica Communications Open Access 18 December 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Planté-Bordeneuve, V. & Said, G. Familial amyloid polyneuropathy. Lancet Neurol. 10, 1086–1097 (2011).
Johnson, S. M. et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. J. Mol. Biol. 5 Jan 2012 (doi: 10.1016/j.jmb.2011.12.060).
Miroy, G. J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl Acad. Sci. USA 93, 15051–15056 (1996).
Razavi, H. et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. Angew. Chem. Int. Ed. 42, 2758–2761 (2003).
European Medicines Agency (EMA). European Public Assessment Report. EMA website [online], (2011).
Hellman, U. et al. Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish population. Amyloid 15, 181–186 (2008).
Ohya, Y. et al. Manifestations of transthyretin-related familial amyloidotic polyneuropathy:long-term follow-up of Japanese patients after liver transplantation. Surg. Today 41, 1211–1218 (2011).
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Said, G., Grippon, S. & Kirkpatrick, P. Tafamidis. Nat Rev Drug Discov 11, 185–186 (2012). https://doi.org/10.1038/nrd3675
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd3675
This article is cited by
-
Chance or challenge, spoilt for choice? New recommendations on diagnostic and therapeutic considerations in hereditary transthyretin amyloidosis with polyneuropathy: the German/Austrian position and review of the literature
Journal of Neurology (2021)
-
Hereditäre Transthyretinamyloidose (ATTRv-Amyloidose)
DGNeurologie (2020)
-
Diagnosis and management of transthyretin familial amyloid polyneuropathy in Japan: red-flag symptom clusters and treatment algorithm
Orphanet Journal of Rare Diseases (2018)
-
Cardiac Amyloidosis: Diagnosis and Treatment Strategies
Current Oncology Reports (2017)
-
Epidemiology of transthyretin-associated familial amyloid polyneuropathy in the Majorcan area: Son Llàtzer Hospital descriptive study
Orphanet Journal of Rare Diseases (2014)
